Vitamin D: How Much You Actually Need (and Why the Big Trials Changed the Answer)

Few supplements have had a rise and fall quite like vitamin D. Through the 2000s and 2010s, the observational literature was extraordinary: low levels tracked with cancer, heart disease, diabetes, depression, autoimmune disease, infections, fractures, and death. Testing became routine. Recommended doses climbed. “Optimizing” your vitamin D became a standard piece of health advice.

Then the randomized trials reported, and the story changed almost completely.

This is one of the most instructive episodes in modern nutrition science, and it’s worth understanding not just for vitamin D itself but for how it should change the way you read the next supplement that looks this promising.

---

Two Questions That Keep Getting Conflated

Almost all of the confusion here comes from collapsing two very different questions into one.

Does correcting real deficiency help? Yes, unambiguously. Severe vitamin D deficiency causes rickets in children and osteomalaciaosteomalacia Softening of the bones in adults caused by severe, prolonged vitamin D deficiency. The adult equivalent of rickets in children. in adults. That’s settled, it’s why we fortify milk, and nothing in the trial literature challenges it.

Does raising an already-adequate level higher prevent disease? This is the claim the supplement market is built on, and it is the one the trials tested.

Keep those separate and the evidence becomes much easier to read.

---

Where “30 ng/mL” Came From

In 2011, two authoritative bodies published guidance and landed on different numbers.

The Institute of Medicine reviewed the evidence and set the RDARDA (recommended dietary allowance) The daily intake of a nutrient judged sufficient to meet the needs of about 97.5% of healthy people. It is a population target, not a personal optimum. at 600 IU daily for ages 1–70 and 800 IU for those over 70, corresponding to a blood 25(OH)D25(OH)D (25-hydroxyvitamin D) The storage form of vitamin D measured in blood, and the standard way to assess vitamin D status. Reported in ng/mL in the US and nmol/L elsewhere — multiply ng/mL by 2.5 to convert. level of at least 20 ng/mL — a level the committee concluded meets the requirements of 97.5% of the population. It also noted something that got very little attention: higher levels were not consistently associated with greater benefit, and for several outcomes the association was U-shaped, with risk at both low and high levels.

The same year, an Endocrine Society guideline aimed at evaluating and treating patients at risk for deficiency used 30 ng/mL as its threshold.

Both documents were defensible for their intended purpose. But the higher number escaped its context. It became the cutoff printed on consumer lab reports, which meant a large share of the population got flagged “insufficient” — and a testing-and-supplementation market grew in the ten-nanogram gap between two committees.

---

What the Trials Actually Found

VITAL is the big one: 25,871 US adults (men 50+, women 55+) randomized to 2,000 IU of vitamin D3 daily or placebo, followed for a median of 5.3 years, with co-primary endpoints of invasive cancer and major cardiovascular events.

Neither endpoint moved. Vitamin D did not reduce cancer incidence, and it did not reduce major cardiovascular events.

Fractures were the next thing to fall. A VITAL ancillary study published in 2022 tracked incident fractures in the same population and found no significant reduction in total, nonvertebral, or hip fractures. Notably, these were generally healthy adults not selected for deficiency, low bone mass, or osteoporosis — which is precisely the population that had been buying vitamin D for bone health.

D2d tested prevention in people already heading toward disease: 2,423 adults with prediabetes randomized to 4,000 IU daily — double the VITAL dose — or placebo. Progression to type 2 diabetes occurred in 293 participants on vitamin D versus 323 on placebo, a hazard ratiohazard ratio A number comparing how fast an outcome happens in two groups. Above 1 means more risk in the treated group, below 1 means less, and exactly 1 means no difference. of 0.88 that did not reach statistical significance.

---

The One Result That Didn’t Fail

Honest reporting means including the finding that cuts the other way.

A 2022 VITAL analysis in the BMJ tracked incident autoimmune disease — rheumatoid arthritis, polymyalgia rheumatica, autoimmune thyroid disease, psoriasis and others — over the same period. Confirmed autoimmune disease occurred in 123 participants on vitamin D versus 155 on placebo: a hazard ratio of 0.78 (95% CI 0.61–0.99), about a 22% reduction.

That is a real, prespecified result from a large randomized trial, and it is biologically plausible given vitamin D’s role in immune regulation. It also has a confidence interval whose upper bound is 0.99 and a p-value of 0.05 — it clears the bar by the narrowest possible margin, on an outcome that was initially self-reported before adjudication. It deserves to be taken seriously and replicated, not treated as established.

---

More Is Not Better

The megadosing culture — 5,000 or 10,000 IU daily, sometimes far more — rests on the assumption that if some is good, more is better and the worst case is wasted money.

A three-year randomized trial in JAMA tested that directly, assigning 311 healthy adults aged 55–70 to 400, 4,000, or 10,000 IU daily and measuring bone density with high-resolution imaging. Radial bone density came out lower in both high-dose groups than in the 400 IU group, in a dose-dependent fashion, with tibial density also lower at 10,000 IU.

That is the opposite of the intended effect, in the exact tissue vitamin D is taken to protect. Add the established risks of sustained excess — hypercalcemiahypercalcemia Too much calcium in the blood. Symptoms include nausea, confusion, excessive thirst, and kidney stones. It is the main sign of vitamin D toxicity., kidney stones, kidney injury — and the risk-benefit case for routine high-dose supplementation is genuinely negative rather than merely neutral.

---

The 2024 Reversal

In 2024 the Endocrine Society — the same body whose 2011 document popularized the 30 ng/mL threshold — published new guidance that moved substantially.

It suggests against routine 25(OH)D testing in healthy individuals, on the grounds that outcome-specific benefits of treating to a target have not been established in trials. For adults aged 50–74, it suggests against routine supplementation beyond the RDA, and against routine testing.

It does suggest empiric supplementation — without testing first — for four groups where the trial evidence points toward benefit: children and adolescents (1–18), adults over 75, people who are pregnant, and adults with high-risk prediabetes.

The logic is worth appreciating: for the groups likely to benefit, supplement at modest doses without measuring; for everyone else, don’t measure and don’t supplement beyond the RDA. That is close to the inverse of how vitamin D is handled in most consumer testing panels.

---

Who Should Still Test

Guidelines describe populations; you are a person. Testing remains reasonable if you have a concrete reason to be deficient:

• Malabsorption — celiac disease, Crohn’s, prior bariatric surgery
• Chronic kidney or liver disease, which impair activation of the vitamin
• Osteoporosis or a fragility fracture, where deficiency should be excluded before treatment
• Medications — long-term glucocorticoidsglucocorticoid A class of steroid anti-inflammatory drugs, such as prednisone. Long-term use thins bone and interferes with vitamin D and calcium handling., certain antiseizure drugs
• Very limited sun exposure — housebound, fully covered clothing, or high-latitude winter with dark skin
• Obesity, where sequestration in adipose tissue lowers circulating levels

Outside those categories, a healthy adult ordering an annual 25(OH)D is mostly buying a number that will not change what they should do. Our annual blood panel guide covers where it sits against tests that carry more decision-making weight.

---

Where This Leaves Us

Vitamin D didn’t fail because the science was fraudulent. It failed because a mountain of observational data pointed at a hypothesis that seemed too consistent to be wrong, and the randomized trials — which are the only design that can separate a marker from a lever — said otherwise.

The residue is still useful. Correct real deficiency. Take the RDA if your diet and sun exposure are thin, or fall into one of the groups the 2024 guideline names. Skip the annual test if you have no reason to be low. And don’t take 10,000 IU because a number on a lab report was printed in red.

---

A note on what’s still open: The autoimmune disease signal is the live question — a modest, borderline-significant reduction in a large randomized trial, extended in follow-up analyses and biologically plausible. If it replicates in a trial designed for that endpoint, it would be the one disease-prevention claim for vitamin D that survives the last decade intact.